In blood platelets the small GTPase Rap1b is activated by cytosolic Ca 2 + and promotes integrin α IIb β 3 inside-out activation and platelet aggregation. cAMP is the major inhibitor of platelet function and antagonizes Rap1b stimulation through a mechanism that remains unclear. In the present study we demonstrate that the Ca 2 + -dependent exchange factor for Rap1b, CalDAG-GEFI (calcium and diacylglycerol-regulated guanine-nucleotide-exchange factor I), is a novel substrate for the cAMP-activated PKA (protein kinase A). CalDAG-GEFI phosphorylation occurred in intact platelets treated with the cAMP-increasing agent forskolin and was inhibited by the PKA inhibitor H89. Purified recombinant CalDAG-GEFI was also phosphorylated in vitro by the PKA catalytic subunit. By screening a panel of specific serine to alanine residue mutants, we identified Ser 116 and Ser 586 as PKA phosphorylation sites in CalDAG-GEFI. In transfected HEK (human embryonic kidney)-293 cells, as well as in platelets, forskolin-induced phosphorylation of CalDAG-GEFI prevented the activation of Rap1b induced by the Ca 2 + ionophore A23187. In platelets this effect was associated with the inhibition of aggregation. Moreover, cAMP-mediated inhibition of Rap1b was lost in HEK-293 cells transfected with a double mutant of CalDAG-GEFI unable to be phosphorylated by PKA. The results of the present study demonstrate that phosphorylation of CalDAG-GEFI by PKA affects its activity and represents a novel mechanism for cAMP-mediated inhibition of Rap1b in platelets.
INTRODUCTION
Integrin α IIb β 3 -mediated fibrinogen binding and platelet aggregation are essential events in haemostasis and thrombosis. Resting platelets are unable to aggregate because integrin α IIb β 3 is maintained in a low affinity conformation for soluble fibrinogen. Platelet stimulation induced by adhesion receptors or by soluble agonists culminates with the inside-out activation of integrin α IIb β 3 and its conversion into the high-affinity conformation, thus promoting fibrinogen binding [1, 2] . The signalling pathways involved in integrin α IIb β 3 inside-out activation have been dissected and the importance of many signalling molecules, including the small GTPase Rap1b, has been clearly established [3] [4] [5] [6] . Rap1b is a Ras-like small GTPase that cycles between an inactive GDP-bound state and an active GTP-bound state in response to platelet stimulation. Upon activation, Rap1b binds its effector RIAM (Rap1-GTP-interacting adaptor molecule) and promotes the association of cytoskeletal proteins, such as talin and kindlin, to the integrin β tails stimulating the conformational change of integrin α IIb β 3 into its active state [7] [8] [9] [10] [11] [12] .
As for other GTPases, Rap1b activity in platelets is controlled by two sets of accessory proteins: GEFs (guanine-nucleotideexchange factors), that stimulate the release of GDP and the binding of GTP triggering Rap1b activation and GAPs (GTPase-activating proteins), that stimulate the intrinsic Rap1b GTPase activity and restore the GDP-bound inactive state [13] . Different GEFs for Rap proteins have been identified [14] . In platelets, the Ca 2 + and DAG (diacylglycerol)-regulated CalDAG-GEFI [calcium and DAG-regulated guanine-nucleotide-exchange factor I; also known as RasGRP2 (RAS guanyl-releasing protein 2)] has been recognized as the major regulator of Rap1b activation [3, 4, 15, 16] , whereas the expression of other GEFs, such as PDZ-GEF and CalDAG-GEFIII, remains controversial [17, 18] . Previous studies have demonstrated that platelets from CalDAG-GEFI-knockout mice show defective Rap1b activation upon stimulation with a number of soluble agonists, as well as upon adhesion to collagen, and display impaired integrin α IIb β 3 inside-out activation, aggregation, secretion and TxA 2 (thromboxane A2) production [19, 20] . Moreover, CalDAG-GEFI-knockout mice showed a reduced thrombus formation in a model of Fe 3 Cl arterial thrombosis in vivo [3, 21] .
CalDAG-GEFI contains two atypical Ca 2 + -binding EF hand domains and an atypical DAG-binding C1 domain, in addition to a REM (Ras-exchange motif) and a CDC25 domain. The functional relevance of EF hand domains is documented by the observation that intracellular Ca 2 + can directly induce the CalDAG-GEFIdependent activation of Rap1b [3] . The C1 domain of CalDAG-GEFI is predicted to have only a weak affinity for DAG; however, it certainly plays a major physiological role as its deletion is associated with impaired integrin activation and reduced arterial thrombosis [21] .
In the present study we investigated possible additional mechanisms regulating CalDAG-GEFI activity. Using different experimental approaches we demonstrated that CalDAG-GEFI Abbreviations used: CalDAG-GEFI, calcium and diacylglycerol-regulated guanine-nucleotide-exchange factor I; DAG, diacylglycerol; DTT, dithiothreitol; EPAC, exchange factor directly activated by cAMP 1; GAP, GTPase-activating protein; GEF, guanine-nucleotide-exchange factor; GST, glutathione transferase; HA, haemagglutinin; HEK, human embryonic kidney; PKA, protein kinase A; Rap1GAP2, RAP1 GTPase-activating protein 2; TxA 2 , thromboxane A2. 1 To whom correspondence should be addressed (email mauro.torti@unipv.it).
is a substrate for PKA (protein kinase A) and showed that PKA-directed phosphorylation can negatively regulate Rap1b activation.
MATERIALS AND METHODS

Materials
pCMV-Sport-CalDAG-GEFI was a gift from Dr Jill Crittenden (Harvard Medical School, Boston, MA, U.S.A.). pMT2-Rap1b was provided by Professor Johannes L. Bos (University Medical Centre, Utrecht, The Netherlands). pGEX4T3 was from GE Healthcare. Pfu Turbo polymerase was from Stratagene. Gel Extraction Kit was from Qiagen. Bio-Scale Mini Profinity GST Cartridges were from Bio-Rad Laboratories. [γ -
32 P]ATP and [ 32 P]orthophosphate were purchased from PerkinElmer. Lipofectamine TM 2000 was from Invitrogen. PP2 and Ro31-8220 were from Calbiochem. Forskolin, A23187, H89, W7 and the purified PKA catalytic subunit were from Sigma-Aldrich. The rabbit polyclonal antibodies against Rap1 (121) and a HA (haemagglutinin) tag (Y-11) were from Santa Cruz Biotechnology. The rabbit polyclonal antibody against PKA (phospho)substrates was from Cell Signaling Technology. The anti-FLAG antibody (M2) was from Sigma-Aldrich. The rabbit polyclonal anti-CalDAG-GEFI antibody was a gift from Professor Wolfgang Bergmeier (University of North Carolina, Chapel Hill, NC, U.S.A.).
Cloning, purification and mutagenesis of GST (glutathione transferase)-CalDAG-GEFI
The coding sequence of C-terminally FLAG-tagged CalDAG-GEFI from Rattus norvegicus was subcloned from pCMVSport plasmid into the prokaryotic expression vector pGEX4T3. The CalDAG-GEFI sequence was amplified in a PCR using the Pfu Turbo DNA polymerase and the primers forward, 5 -TAAGTCGACGCGAGCACTCTGGACCTGGACA-3 and reverse, 5 -AGAGCGGCCGCTCATTTATCGTCATC-3 . The consensus sequences for the restriction enzymes SalI (in the forward primer) and NotI (in the reverse primer) are shown in bold.
The PCR product and pGEX4T3 plasmid were double digested with SalI and NotI, separated by agarose gel electrophoresis, purified using a gel extraction kit and eventually ligated. The accuracy of the cloning procedure was verified by PCR, restriction enzyme digestion and plasmid sequencing. The pGEX plasmid containing the coding sequence for the GST-tagged CalDAG-GEFI was transformed into the Escherichia coli BL21 strain and the GST-CalDAG-GEFI protein was purified by affinity chromatography using Bio-Scale Mini Profinity GST Cartridges as described previously [22] . The protein concentration was determined by SDS/PAGE (10 % gel) and densitometric analysis with the ImageJ software (http://rsbweb.nih.gov/ij/) using BSA as a standard for quantification.
CalDAG-GEFI phospho-mutants (S116A, S117A, S147A, S586A, S116/117A, S116/586A, S117/586A and S116/117/ 586A) were obtained by site-directed mutagenesis starting from the mammalian vector pCMV-Sport containing the coding sequence corresponding to the C-terminally FLAG-tagged CalDAG-GEFI of R. norvegicus. In order to introduce the different mutations the following primers were used (double and triple mutants were produced by sequential mutagenesis reactions): S116A forward, 5 -GGAAACCGCAGGCACGCCAGCCTCA-TCGACAT-3 and reverse, 5 -ATGTCGATGAGGCTGGCG-TGCCTCGGTTTCC-3 ; S117A forward, 5 -ACCGCAGGCA-CAGCGCCCTCATCGACATCG-3 and reverse, 5 -CGATG-TCGATGAGGGCGCTGTGCCTGCGGT-3 ; S147A forward, 5 -CAGAAAAAGCGCAAGATGGCCCTGTTGTTTGATCACT-3 and reverse, 5 -AGTGATCAAACAACAGGGCCATCTTGCG-CTTTTTCTG-3 ; S586A forward, 5 -GCAGGCGCAGCGC-TCGGCCTCCA-3 and reverse, 5 -TGGAGGCCGAGCGCTG-CGCCTGC-3 ; and S116/117A forward, 5 -GAAACCGCA-GGCACGCCGCCCTCATCGACA-3 and reverse, 5 -TGTCG-ATGAGGGCGGCGTGCCTGCGGTTTC-3 .
Platelet isolation and preparation of platelet extract
Whole blood, anticoagulated with citric acid/citrate/dextrose (152 mM sodium citrate, 130 mM citric acid and 112 mM glucose), was collected by the staff of the Transfusion Department of the IRCCS 'San Matteo' Hospital, Pavia, Italy, from informed healthy volunteers as approved by the internal Institution Review Board. Blood was centrifuged at 120 g for 10 min at room temperature (20) (21) (22) (23) (24) (25) • C). Apyrase (0.2 units/ml) and prostaglandin E 1 (1 μM) were added to platelet-rich plasma, platelets were recovered by centrifugation at 720 g for 15 min, washed with 10 ml of Pipes buffer (20 mM Pipes and 137 mM NaCl, pH 6.5) and finally gently resuspended in Hepes buffer (10 mM Hepes, 137 mM NaCl, 2.9 mM KCl and 12 mM NaHCO 3 , pH 7.4). The cell count was adjusted to 1×10 9 platelets/ml and 5.5 mM glucose was added. For some experiments, platelets were further diluted to 0.3×10 9 cells/ml. The platelet cytosolic extract was prepared by sonication on ice of 1 ml of washed human platelets at the final concentration of 1×10 9 cells/ml in Hepes buffer supplemented with 10 μg/ml aprotinin, 10 μg/ml leupeptin and 2 mM PMSF. A total of three sonication cycles of 15 s were performed using a MSE Soniprep 150 provided with a microprobe and set at the maximum power. The insoluble fraction was recovered by centrifugation for 3 min at 8000 g at 4
• C and discharged, whereas the supernatant was used for the subsequent assay.
In vitro phosphorylation assays
Samples of 0.3 ml were prepared in Hepes buffer by mixing 0.5 μg of recombinant GST-CalDAG-GEFI, or purified GST as a negative control, with aliquots of the platelet sonicate (0.2 ml per sample) or with the purified catalytic subunit of PKA (5 units/ml), in the presence of 10 mM MgCl 2 , 1 mM DTT (dithiothreitol), 0.1 % Triton X-100, 50 μM cold ATP and 10 μCi [γ -32 P]ATP. After incubation for various lengths of time, the kinase reaction was stopped by the addition of 0.3 ml of ice-cold modified 2× RIPA buffer (100 mM Tris/HCl, pH 7.4, 400 mM NaCl, 5 mM MgCl 2 , 2% Nonidet P-40, 20 % glycerol, 0.2 μM aprotinin, 2 μM leupeptin, 2 mM PMSF, 2 mM Na 3 VO 4 and 2mM NaF). The GST proteins were precipitated by incubation for 1 h with 30 μl of GSH-Sepharose, washed three times with modified RIPA buffer and finally dissociated with 25 μl of 2× SDS-sample buffer and heated at 95
• C for 3 min. Proteins were separated by SDS/PAGE (10 % gel), which was stained with Coomassie Blue and then analysed by autoradiography as described previously [23] . In selected experiments, the assay was performed in the presence of cAMP (1 μM), or different protein kinase inhibitors (10 μM PP2, 10 μM Ro31-8220, 100 μM W7 or 10 μM H89). When the analysis of CalDAG-GEFI phosphorylation was performed by immunoblotting with the anti-PKA (phospho)substrates antibody, the assay was performed in the absence of [γ -
32 P]ATP.
Platelet stimulation and analysis of platelet aggregation
Washed platelets (0.3 ml, 0.3×10 9 platelets/ml) were either left untreated or pre-incubated with forskolin in the presence of 100 nM CaCl 2 , and then stimulated with 100 nM A23187 for different lengths of time. Stimulation was stopped by the addition of 0.3 ml of ice-cold modified 2× RIPA buffer. Clarified lysates were either immediately dissociated with 0.5 volume of 3× SDS sample buffer (37.5 mM Tris/HCl, pH 8.3, 288 mM glycine, 6 % SDS, 1.5 % DTT, 30 % glycerol and 0.03 % Bromophenol Blue) and heated at 95
• C for 3 min for the total immunoblotting analyses, or used for subsequent analysis of Rap1b activation or immunoprecipitation of CalDAG-GEFI. Analysis of platelet aggregation was performed in a Born lumiaggregometer at 37
• C under stirring in the presence of 100 nM CaCl 2 , essentially as described previously [24] . Platelet aggregation was monitored for 5 min.
Cell culture, transfection and stimulation
Human 1321N1 astrocytoma cells and HEK (human embryonic kidney)-293 cells were maintained in DMEM (Dulbecco's modified Eagle's medium) and RPMI 1640 medium respectively, supplemented with 10 % fetal bovine serum, 2 mM L-glutamine, 100 units/ml penicillin and 100 μg/ml streptomycin. Semiconfluent 1321N1 or HEK-293 cells, cultured in 100 mm dishes, were transiently transfected with 3 μg of the different plasmids using Lipofectamine TM 2000 according to the manufacturer's protocol. At 16 h after transfection, the adherent cells were washed with Hepes buffer and then either left untreated or pre-incubated for 15 min with 20 μM H89 before being treated with 10 μM forskolin and/or 500 nM A23187 as described in the Figure legends. Cells were then lysed with 0.8 ml of ice-cold modified RIPA buffer and the lysates were clarified by centrifugation at 18 000 g in a microcentrifuge for 10 min at 4
• C. Total samples for immunoblotting analyses were prepared by dissociating 0.1 ml aliquots of the clarified lysates with 0.05 ml of 3× SDS sample buffer and heating for 3 min at 95
• C. The remaining clarified lysates were subsequently used for the immunoprecipitation of CalDAG-GEFI or for the analysis of Rap1b activation as described below.
Metabolic labelling of the transfected 1321N1 cells was performed with 50 μCi/ml of [ 32 P]orthophosphate in Hepes buffer for 3 h and 37
• . The labelling buffer was recovered and the dishes were washed once with 5 ml of Hepes buffer. Stimulation of adherent cells was then performed as described above.
Rap1b activation assay
Activation of Rap1b was evaluated in lysates from stimulated platelets or HEK-293 cells by a pull-down assay using the GST-tagged Rap-binding domain of RalGDS (GST-RalGDS-RBD) essentially as described previously [4] . Proteins were then separated by SDS/PAGE (10-20 % gradient gel), transferred on to PVDF membranes and probed by immunoblotting with an antiRap1 antibody or anti-HA antibody for the analyses in platelets and HEK-293 cells respectively.
Immunoprecipitation
Cleared HEK-293 cell lysates were incubated with 2 μg of anti-FLAG antibody for 2 h at 4
• C and the immunocomplexes were precipitated by the addition of 70 μl of a suspension of Protein A-Sepharose (50 mg/ml). Endogenous CalDAG-GEFI was immunoprecipitated from platelet lysates using 2 μg of an anti-CalDAG-GEFI antibody and subsequent incubation with Protein A-Sepharose. After 45 min of incubation at 4
• C, immunoprecipitates were recovered by centrifugation, washed three times with modified RIPA buffer and finally dissociated with 25 μl of 2× SDS sample buffer and heated at 95
• C for 3 min. Immunoprecipitated proteins were then separated by SDS/PAGE (10 % gel), transferred on to PVDF membranes and then analysed by immunoblotting or autoradiography.
Statistical analysis
All the Figures are representative of at least three independent experiments. The quantification of protein phosphorylation was performed by band density analysis with ImageJ software. Statistical analysis was performed using Prism 4 Graphpad software and the data were compared using one-way ANOVA and Bonferroni's post-hoc test.
RESULTS
CalDAG-GEFI is phosphorylated in vitro by PKA
The possible phosphorylation of CalDAG-GEFI in human platelets, was initially investigated by in vitro kinase assays. Purified recombinant GST-CalDAG-GEFI, as well as purified GST as a negative control, was incubated with a cytosolic platelet extract for increasing periods of time in the presence of [γ -32 P]ATP. Recombinant proteins were then precipitated with GSHSepharose and analysed by SDS/PAGE followed by Coomassie Blue staining and autoradiography. As shown in Figure 1(A) , GST-CalDAG-GEFI, which migrated on SDS/PAGE with an apparent molecular mass of approximately 100 kDa, incorporated 32 P from labelled ATP in the presence of platelet extract, whereas, under the same conditions, GST alone was not labelled. No phosphorylation of CalDAG-GEFI was observed in the absence of platelet lysate, confirming that platelets provided the kinasemediating CAlDAG-GEFI phosphorylation.
To identify the platelet kinase(s) responsible for CalDAG-GEFI phosphorylation, we tested the effect of a number of pharmacological inhibitors for the most common platelet kinases. Whereas no significant effects were produced by inhibition of Src family kinases by PP2, protein kinase C by Ro31-8220 or Ca 2 + /calmodulin-dependent kinases by W7, we found that the PKA inhibitor H89 was able to strongly prevent the GST-CalDAG-GEFI phosphorylation promoted by a platelet lysate ( Figure 1B) . The involvement of PKA in CalDAG-GEFI phosphorylation was supported by the finding that the addition of cAMP to the reaction mixture strongly increased GST-CalDAG-GEFI phosphorylation, an effect that was dose-dependently reversed by H89 ( Figure 1C ).
CalDAG-GEFI phosphorylation was also detected in assays in which the platelet extract was replaced with the purified PKA catalytic subunit. Indeed, as shown in Figure 1D , incubation with purified PKA in the presence of [γ -32 P]ATP induced a marked phosphorylation of GST-CalDAG-GEFI. This result was also confirmed by a different technical approach, in which the kinase assay was performed in the presence of cold nonradiolabelled ATP, and CalDAG-GEFI phosphorylation was detected by immunoblotting with an antibody that specifically recognizes phosphorylated PKA substrates ( Figure 1E ).
Phosphorylation of CalDAG-GEFI in transfected cells and in platelets
In order to determine whether CalDAG-GEFI phosphorylation by PKA also occurred in whole cells, 1321N1 astrocytoma cells were transfected with FLAG-tagged CalDAG-GEFI and then metabolically labelled with [ 32 P]orthophosphate. Cells were then treated with forskolin to increase intracellular cAMP, either in the presence, or in the absence of the PKA inhibitor H89. Upon cell lysis, CalDAG-GEFI was immunoprecipitated with an anti-FLAG antibody, and the incorporation of [ 32 P]phosphate was evaluated by autoradiography. As shown in Figure 2 (A), exogenous FLAG-tagged CalDAG-GEFI was slightly phosphorylated in transfected cells and treatment with forskolin induced a rapid and robust increase of phosphorylation that was sustained at least for 20 min. Moreover, forskolininduced phosphorylation was effectively prevented by the preincubation with the PKA inhibitor H89. The same observation was also confirmed by analysing the immunoprecipitated proteins by immunoblotting with the anti-PKA (phospho)substrates antibody ( Figure 2B ). We next analysed whether the phosphorylation of CalDAG-GEFI also occurred in platelets, where this protein represents the major regulator of Rap1b activation [19, 20] . Washed human platelets were treated with forskolin for increasing periods of time and endogenous CalDAG-GEFI was immunoprecipitated with a specific antibody and subsequently analysed by immunoblotting with the anti-PKA (phospho)substrates antibody. As negative control, aliquots of the same platelet lysates were immunoprecipitated with a non-related antibody. Figure 2(C) shows that platelet CalDAG-GEFI was rapidly phosphorylated in platelets upon the increase in intracellular cAMP. Indeed, CalDAG-GEFI phosphorylation was evident from 30 s up to 3 min upon the exposure of platelets to forskolin.
CalDAG-GEFI is phosphorylated by PKA on two distinct serine residues
Although CalDAG-GEFI was found to be phosphorylated by PKA in human platelets, the in vitro kinase assays and the (C) Washed human platelets were pre-incubated with 10 μM forskolin for increasing times and endogenous CalDAG-GEFI was immunoprecipitated with a specific anti-CalDAG-GEFI antibody. Control immunoprecipitation was performed with a non-related antibody (NRA). The immunoprecipitated proteins were analysed by immunoblotting with anti-PKA (phospho)substrates and then reprobed with the anti-CalDAG-GEFI antibody, as indicated on the right-hand side. All the results are representative of at least three independent experiments. Molecular mass is shown on the left-hand side in kDa.
studies with transfected cells were performed using rat CalDAG-GEFI cDNA. The computational analysis of the rat CalDAG-GEFI sequence with the NetPhosK software, which detects the presence of conserved kinase consensus sequences, revealed that serine residues at positions 116, 117, 147 and 586 had the highest probability of being phosphorylation sites for PKA.
These residues are also conserved in CalDAG-GEFI of mouse and human origin ( Figure 3A) . In order to precisely identify the PKA phosphorylation sites, selective serine to alanine mutants for these four residues were generated by site-directed mutagenesis. The mutants were expressed in 1321N1 cells and their forskolin-induced phosphorylation was evaluated by immunoblotting analysis of whole-cell lysates with the anti-PKA (phospho)substrates antibody. Compared with the wildtype CalDAG-GEFI, an evident reduction of phosphorylation was observed in the S116A and S586A mutants. The S117A mutant displayed a modest, but not significant, reduction in phosphorylation, whereas the substitution of Ser 147 with an alanine residue did not alter CalDAG-GEFI phosphorylation ( Figure 3B) . We next generated different CalDAG-GEFI double mutants for the residues 116, 117 and 586 and a triple mutant in which all the three serine residues were replaced with alanine. The immunoblotting analysis reported in Figure 3(C) shows that the phosphorylation of the S116/117A and S117/586A double mutants was decreased compared with that of wild-type CalDAG-GEFI, but not abolished, whereas the phosphorylation of the double mutant S116/586A was essentially suppressed, as it was that of the triple mutant ( Figure 3C ). These observations indicate that Ser 116 and Ser 586 , but not Ser 117 , represent the major phosphorylation sites for PKA on rat CalDAG-GEFI.
In order to confirm these results, the phosphorylation of the S116/586A double mutant and S116/117/586A triple mutant was also analysed by autoradiography of the immunoprecipitated proteins from 32 P-labelled transfected 1321N1 cells. As shown in Figure 3(D) , the simultaneous mutation of Ser 116 and Ser 586 abolished the forskolin-induced phosphorylation of CalDAG-GEFI, as the residual phosphorylation observed was comparable with that detected in untreated cells. The phosphorylation of the triple mutant was essentially identical to that of the double mutant, confirming that Ser 117 does not represent an additional PKA phosphorylation site ( Figure 3D ). Identical results were also obtained by immunoblotting analysis with the anti-PKA (phospho)substrates antibody that was performed on the immunoprecipitated proteins (results not shown).
The phosphorylation of CalDAG-GEFI inhibits its activity
We next addressed the question about the physiological consequence of CalDAG-GEFI phosphorylation by PKA on platelet function. It is well known that cytosolic cAMP causes platelet inhibition and that many of the effects triggered by cAMP elevation in platelets are mediated by PKA. CalDAG-GEFI is the major regulator of Rap1b activation in platelets and active Rap1b is critical for several platelet responses, including integrin α IIb β 3 inside-out activation and platelet aggregation. Therefore we hypothesized that CalDAG-GEFI phosphorylation by PKA could prevent agonist-induced Rap1b activation. Since PKA phosphorylates multiple targets in platelets, and therefore it may hamper different steps in the signal transduction pathways stimulated by extracellular agonists, we evaluated the effect of cAMP on Rap1b activation upon direct stimulation of CalDAG-GEFI by cytosolic Ca 2 + increase. As shown in Figure 4 (A), treatment of intact platelets with the Ca 2 + ionophore A23187 induced a robust activation of Rap1b. Pre-incubation of platelets with forskolin, causing CalDAG-GEFI phosphorylation, completely suppressed the Rap1b activation induced by A23187. These results indicate that intracellular Ca 2 + failed to stimulate the activity of PKA-phosphorylated CalDAG-GEFI. Importantly, the treatment with forskolin also suppressed Ca 2 + ionophoreinduced platelet aggregation ( Figure 4B) , which was previously shown to also depend on CalDAG-GEFI [3] . 
Figure 4 CalDAG-GEFI phosphorylation by PKA impairs Rap1b activation
(A) Human washed platelets, pre-incubated with vehicle (none) or with 10 μM forskolin for 5 min (FSK), were stimulated with 100 nM A23 187 in the presence of 100 nM CaCl 2 for increasing periods of time. Upon platelet lysis, GTP-Rap1b was precipitated by a pull-down assay using the GST-RalGDS-RBD probe and identified by immunoblotting with an anti-Rap1 antibody. The presence of comparable amount of Rap1b in aliquots of the all platelet samples is shown in the lower panel. (B) Washed platelets were left untreated (none) or pre-incubated with 10 μM forskolin for 2 min (FSK) and then stimulated with 100 nM A23 187 in the presence of 100 nM CaCl 2 . Platelet aggregation was monitored for 5 min. (C) HEK-293T cells were transfected with HA-tagged Rap1b alone or co-transfected with HA-tagged Rap1b in association with either wild-type CalDal-GEFI (WT) or the S116/586A double mutant CalDAG-GEFI as indicated. Cells were left untreated (none) or stimulated with A23187 (500 nM, 3 min) in the absence or presence of forskolin (FSK; 10 μM, 5 min). Upon cell lysis, aliquots of the samples were used to evaluate the activation of exogenous Rap1b through the pull-down assay with the GST-RalGDS-RBD, followed by immunoblotting with an anti-HA antibody (Rap1b-GTP). Aliquots of whole-cell lysates were analysed by immunoblotting with the anti-HA antibody to compare the expression of exogenous Rap1b (Rap1b TOT) with the anti-PKA (phospho)substrates antibody, to determine the phosphorylation of CalDAG-GEFI (P-CalDAG-GEFI), and with the anti-FLAG antibody, to verify the expression of the wild-type and mutant proteins (CalDAG-GEFI). All of the reported results are representative of at least three independent experiments. Molecular mass is shown on the left-hand side of the blots in kDa.
In order to confirm the inhibitory effect of phosphorylation on CalDAG-GEFI activity, we analysed Ca 2 + -induced Rap1b activation in HEK-293 cells transfected to express Rap1b in association with either wild-type CalDAG-GEFI or the nonphosphorylable S116/586A double mutant. As observed for 1321N1 cells, wild-type CalDAG-GEFI, but not the S116/586A double mutant, was phosphorylated by PKA upon the exposure of HEK-293 cells to forskolin ( Figure 4C ).
When HEK-293 cells were transfected with Rap1b and wildtype CalDAG-GEFI, treatment with A23187 caused an evident accumulation of GTP-bound Rap1b, which was clearly promoted by CalDAG-GEFI activity since it was not observed in cells transfected with Rap1b alone ( Figure 4C ). Under these conditions, elevation of cAMP by forskolin prevented CalDAG-GEFImediated Rap1b stimulation. Interestingly, Ca 2 + ionophoreinduced activation of Rap1b was also observed in cells cotransfected with the S116/586A double mutant of CalDAG-GEFI. However, in this case Rap1b activation was no longer prevented by the treatment of cells with forskolin. These results indicate that the ability of increased cAMP to prevent Rap1b stimulation relies on PKA-mediated phosphorylation of CalDAG-GEFI.
DISCUSSION
In the present study we demonstrated that CalDAG-GEFI, the major activator of the small GTPase Rap1b in circulating blood platelets, is a novel substrate for PKA. We found that PKA phosphorylation of CalDAG-GEFI occurs at two distinct sites, namely Ser 116 and Ser 586 , and prevents the ability of CalDAG-GEFI to stimulate GTP binding of Rap1b.
Elevation of cAMP in circulating platelets by endothelial cell-derived prostaglandins leads to the activation of PKA, and represents the major physiological strategy to inhibit platelet function. Activated PKA phosphorylates many regulatory proteins preventing platelet responses to extracellular agonists, such as phospholipase C activation, granule secretion, TxA 2 production and integrin α IIb β 3 inside-out activation, which is required for fibrinogen binding and for the subsequent platelet aggregation [25] . The small GTPase Rap1b is a key element in the inside-out pathway for integrin α IIb β 3 activation. Agonistinduced stimulation of Rap1b in platelets is primarily mediated by CalDAG-GEFI and is prevented by PKA activation, although the precise mechanism for this inhibitory effect was unclear [25, 26] . In the present study, we demonstrated that PKA-mediated phosphorylation of CalDAG-GEFI is responsible for the reduced Rap1b activation caused by cAMP increasing agents. This process may significantly contribute to the mechanism for cAMPmediated inhibition of platelet aggregation.
In the present study the phosphorylation of CalDAG-GEFI by PKA has been documented both as incorporation of 32 P from radiolabelled ATP and by immunoblotting analysis with an anti-PKA (phospho)substrates antibody, and was observed to occur in in vitro kinase assays with purified proteins in intact platelets treated with the cAMP-increasing agent forskolin and in transfected cells.
By computational analysis-assisted site-directed mutagenesis we identified Ser 116 and Ser 586 as the sites of PKA phosphorylation. Substitution of these two serine residues with alanine was sufficient to completely abolish PKA-mediated CalDAG-GEFI phosphorylation in transfected cells. Two additional potential PKA phosphorylation sites are present on CalDAG-GEFI, Ser 117 and Ser 147 , however, in our assays, these residues did not appear to contribute to CalDAG-GEFI phosphorylation. Interestingly, evaluation of 32 P incorporation on CalDAG-GEFI in metabolically labelled cells revealed a residual phosphorylation of the S116/586A CalDAG-GEFI double mutant both in quiescent and in forskolin-treated cells, indicating that CalDAG-GEFI may also be phosphorylated by kinases other than PKA.
In the present study, CalDAG-GEFI cDNA of rat origin was used for eukaryotic cell transfection as well as for recombinant protein purification. However, we found that human CalDAG-GEFI endogenously expressed in blood platelets is similarly phosphorylated by PKA. Interestingly, sequence alignment revealed that the identified phosphorylation sites on rat CalDAG-GEFI are also conserved in the mouse and human isoforms. Therefore it may be concluded that in human platelets PKAmediated phosphorylation of CalDAG-GEFI is likely to occur on Ser 116 and Ser 587 . However, the possibility that additional phosphorylation sites, that cannot be identified with these methods, exist cannot be excluded.
We also provided evidence that the PKA-mediated phosphorylation of human CalDAG-GEFI in platelets affects its activity, as it is associated with the inhibition of Ca 2 + -induced Rap1b activation and platelet aggregation. In platelets stimulated by different physiological agonists, such as thrombin, collagen or ADP, CalDAG-GEFI is mainly activated by an increase in intracellular Ca 2 + . It is known that cAMP elevation affects multiple early steps in the agonist-activated signal transduction pathways, resulting in a reduced Ca 2 + mobilization. Therefore since platelet treatment with cAMP-increasing agents, such as forskolin, may affect the pathway leading to CalDAG-GEFI activation, the consequence of PKA-mediated phosphorylation on CalDAG-GEFI activity towards Rap1b was evaluated upon direct stimulation of CalDAG-GEFI with the Ca 2 + ionophore A23187, rather than stimulation with physiological agonists. The results of the present study clearly demonstrate that when CalDAG-GEFI in intact platelets is phosphorylated by PKA, its ability to be stimulated by Ca 2 + and to promote Rap1b activation is abrogated. Owing to the abundance of PKA targets in platelets, and to the multiplicity of pathways for platelet activation, the possibility that other phosphorylated substrates participate in the inhibition of agonist-induced Rap1b activation cannot be confidently excluded. For instance, it is known that ADPstimulated Rap1b activation occurs through a Ca 2 + -independent mechanism, as it is mediated by the G i -coupled P2Y12 receptor rather than by the G q -coupled P2Y1 receptor [27, 28] . Moreover, CalDAG-GEFI has been implicated in the rapid, but not in the delayed, activation of Rap1b by ADP [3, 29] . Nevertheless, we observed that treatment of platelets with forskolin, under conditions of CalDAG-GEFI phosphorylation, prevented both the rapid and delayed activation of Rap1b in ADP-stimulated platelets (results not shown), supporting the possibility that cAMP and PKA affect Rap1b activation by multiple mechanisms. It should be noted, for instance, that PKA is also able to phosphorylate Rap1b itself, and that this phosphorylation affects its subcellular localization. However, it has been demonstrated clearly that PKA phosphorylation of Rap1b does not influence its activation [30] . PKA can also phosphorylate the only GAP for Rap1 found in platelets, Rap1GAP2 (RAP1 GTPase-activating protein 2), promoting its dissociation from 14-3-3 protein. The binding to 14-3-3 protein attenuates the activity of Rap1GAP2, and the phosphorylation by PKA and the subsequent detachment from 14-3-3 protein may represent a mechanism of activation of Rap1GAP2 [17, 25, 31] . Therefore this event may actually contribute to the inhibition of Rap1b activity. However, in support of our conclusion that phosphorylation of CalDAG-GEFI is the major mechanism preventing Rap1b activation by Ca 2 + in platelets, we provide evidence obtained in transfected nucleated cell lines showing that the ability of cAMP to prevent the Ca 2 + -induced activation of Rap1b is lost by the expression of CalDAG-GEFI mutants that cannot be phosphorylated by PKA. These studies were performed on HEK-293 cells rather than on 1321N1 cells that have been used previously for analysis of CalDAG-GEFI phosphorylation, because 1321N1 cells were found to express the cAMP-activated Rap1GEF EPAC1 (exchange factor directly activated by cAMP 1; also known as RAPGEF3; results not shown), which would lead to Rap1b activation upon treatment with the cAMP-increasing agent forskolin. By contrast HEK-293 cells do not express any cAMP-activated Rap1GEF [32] , and had been used previously to reconstitute the CalDAG-GEFI/Rap1b axis and to analyse Ca 2 + -dependent Rap1b activation [33] . In control experiments, CalDAG-GEFI was found to also be phosphorylated by PKA on Ser 116 and Ser 586 in forskolintreated HEK-293 cells. We demonstrated that in HEK-293 cells, Ca 2 + ionophore-induced Rap1b activation through co-expressed wild-type CalDAG-GEFI was inhibited by forskolin treatment, whereas the non-phosphorylable double mutants of CalDAG-GEFI, that were still able to mediate Ca 2 + -induced Rap1b activation, were insensitive to forskolin treatment. Therefore the results of the present study demonstrate that cAMP antagonizes the activation of Rap1b through the phosphorylation of CalDAG-GEFI.
It is known that cAMP can also promote Rap1 protein activation by stimulating the exchange factors of the EPAC subfamily. Therefore cAMP can have opposite effects on Rap1b biology. In this context, it is interesting to note that expression of CalDAG-GEFI and EPAC is mutually exclusive and, to our knowledge, they have never been found co-expressed in the same cell type [18, [34] [35] [36] . In mouse pancreatic acini, Rap1 is activated by both Ca 2 + and cAMP through CalDAG-GEFIII and EPAC respectively [37] ; however, the PKA phosphorylation sites that we have found in CalDAG-GEFI are not conserved in CalDAG-GEFIII.
The precise mechanism for inhibition of Rap1b activity through PKA-mediated phosphorylation of CalDAG-GEFI remains to be elucidated. Phosphorylation may directly reduce the CalDAG-GEFI activity, or may modify its subcellular localization or its association with unidentified interactors. The present study recognizes a novel mechanism for the negative regulation of Rap1b activation by Ca 2 + in human blood platelets and thus opens new perspectives for future investigation on the mechanism regulating platelet function in haemostasis and thrombosis.
AUTHOR CONTRIBUTION
Gianni Francesco Guidetti designed and performed experiments, analysed data and wrote the paper. Daria Manganaro, Alessandra Consonni, Ilaria Canobbio and Cesare Balduini performed experiments and analysed data. Mauro Torti designed the research, analysed data, wrote the paper and was responsible for the overall direction of the present study.
